Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.Most Read from BloombergThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.
Moderna stock falls amid review of bird flu vaccine funds
Moderna's reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due to concerns that the Trump administration might not be as supportive of vaccine manufacturers.
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...
StockStory.org on MSN8d
Why Moderna (MRNA) Stock Is Up TodayShares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...
Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%.
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback